Nzeako UC, Frigas E, Tremaine WJ (November 2001). "Hereditary angioedema: a broad review for clinicians". Arch Intern Med. 161 (20): 2417–29. doi:10.1001/archinte.161.20.2417. PMID11700154.
Ferraro MF, Moreno AS, Castelli EC, Donadi EA, Palma MS, Arcuri HA, et al. (October 2011). "A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family". Allergy. 66 (10): 1384–90. doi:10.1111/j.1398-9995.2011.02658.x. PMID21623829. S2CID23036731.
Weiler CR, van Dellen RG (July 2006). "Genetic test indications and interpretations in patients with hereditary angioedema". Mayo Clin Proc. 81 (7): 958–72. doi:10.4065/81.7.958. PMID16835976.
Donaldson VH, Evans RR (July 1963). "A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C' 1-esterase". Am. J. Med. 35 (1). The American Journal of Medicine: 37–44. doi:10.1016/0002-9343(63)90162-1. PMID14046003.
Dewald G, Bork K (19 May 2006). "Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor". Biochem. Biophys. Res. Commun. 343 (4). Biochemical-and-Biophysical-Research-Communications: 1286–1289. doi:10.1016/j.bbrc.2006.03.092. PMID16638441.
Dewald G (25 March 2018). "A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor". Biochem Biophys Res Commun. 498 (1). Biochemical-and-Biophysical-Research-Communications: 193–198. doi:10.1016/j.bbrc.2017.12.060. PMID29548426.
Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P (May 2001). "Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats". Am. J. Physiol. Heart Circ. Physiol. 280 (5): H2182–8. doi:10.1152/ajpheart.2001.280.5.H2182. PMID11299220. S2CID5898184.
Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO (April 2000). "Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma". Am. J. Physiol. Heart Circ. Physiol. 278 (4): H1069–74. doi:10.1152/ajpheart.2000.278.4.H1069. PMID10749699. S2CID10371501.
Varga L, Farkas H (1 November 2008). "Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor". Expert Review of Clinical Immunology. 4 (6): 653–661. doi:10.1586/1744666X.4.6.653. ISSN1744-666X. PMID20477114. S2CID11656834.
Bernstein JA (January 2008). "Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies". Ann. Allergy Asthma Immunol. 100 (1 Suppl 2): S41–6. doi:10.1016/S1081-1206(10)60585-6. PMID18220151.
"Ruconest EPAR". European Medicines Agency (EMA). 28 October 2010. Retrieved 24 September 2024.
"Firazyr EPAR". European Medicines Agency (EMA). 17 February 2003. Retrieved 24 September 2024.
fda.gov
fda.gov
"Drug Trials Snapshot: Orladeyo". U.S. Food and Drug Administration. 3 December 2020. Retrieved 25 December 2020. This article incorporates text from this source, which is in the public domain.
Nzeako UC, Frigas E, Tremaine WJ (November 2001). "Hereditary angioedema: a broad review for clinicians". Arch Intern Med. 161 (20): 2417–29. doi:10.1001/archinte.161.20.2417. PMID11700154.
Ferraro MF, Moreno AS, Castelli EC, Donadi EA, Palma MS, Arcuri HA, et al. (October 2011). "A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family". Allergy. 66 (10): 1384–90. doi:10.1111/j.1398-9995.2011.02658.x. PMID21623829. S2CID23036731.
Weiler CR, van Dellen RG (July 2006). "Genetic test indications and interpretations in patients with hereditary angioedema". Mayo Clin Proc. 81 (7): 958–72. doi:10.4065/81.7.958. PMID16835976.
Donaldson VH, Evans RR (July 1963). "A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C' 1-esterase". Am. J. Med. 35 (1). The American Journal of Medicine: 37–44. doi:10.1016/0002-9343(63)90162-1. PMID14046003.
Dewald G, Bork K (19 May 2006). "Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor". Biochem. Biophys. Res. Commun. 343 (4). Biochemical-and-Biophysical-Research-Communications: 1286–1289. doi:10.1016/j.bbrc.2006.03.092. PMID16638441.
Dewald G (25 March 2018). "A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor". Biochem Biophys Res Commun. 498 (1). Biochemical-and-Biophysical-Research-Communications: 193–198. doi:10.1016/j.bbrc.2017.12.060. PMID29548426.
Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P (May 2001). "Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats". Am. J. Physiol. Heart Circ. Physiol. 280 (5): H2182–8. doi:10.1152/ajpheart.2001.280.5.H2182. PMID11299220. S2CID5898184.
Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO (April 2000). "Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma". Am. J. Physiol. Heart Circ. Physiol. 278 (4): H1069–74. doi:10.1152/ajpheart.2000.278.4.H1069. PMID10749699. S2CID10371501.
Varga L, Farkas H (1 November 2008). "Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor". Expert Review of Clinical Immunology. 4 (6): 653–661. doi:10.1586/1744666X.4.6.653. ISSN1744-666X. PMID20477114. S2CID11656834.
Bernstein JA (January 2008). "Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies". Ann. Allergy Asthma Immunol. 100 (1 Suppl 2): S41–6. doi:10.1016/S1081-1206(10)60585-6. PMID18220151.
Ferraro MF, Moreno AS, Castelli EC, Donadi EA, Palma MS, Arcuri HA, et al. (October 2011). "A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family". Allergy. 66 (10): 1384–90. doi:10.1111/j.1398-9995.2011.02658.x. PMID21623829. S2CID23036731.
Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P (May 2001). "Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats". Am. J. Physiol. Heart Circ. Physiol. 280 (5): H2182–8. doi:10.1152/ajpheart.2001.280.5.H2182. PMID11299220. S2CID5898184.
Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, Kokkonen JO (April 2000). "Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma". Am. J. Physiol. Heart Circ. Physiol. 278 (4): H1069–74. doi:10.1152/ajpheart.2000.278.4.H1069. PMID10749699. S2CID10371501.
Varga L, Farkas H (1 November 2008). "Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor". Expert Review of Clinical Immunology. 4 (6): 653–661. doi:10.1586/1744666X.4.6.653. ISSN1744-666X. PMID20477114. S2CID11656834.
Varga L, Farkas H (1 November 2008). "Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor". Expert Review of Clinical Immunology. 4 (6): 653–661. doi:10.1586/1744666X.4.6.653. ISSN1744-666X. PMID20477114. S2CID11656834.